AU4781297A - Vaccines - Google Patents

Vaccines

Info

Publication number
AU4781297A
AU4781297A AU47812/97A AU4781297A AU4781297A AU 4781297 A AU4781297 A AU 4781297A AU 47812/97 A AU47812/97 A AU 47812/97A AU 4781297 A AU4781297 A AU 4781297A AU 4781297 A AU4781297 A AU 4781297A
Authority
AU
Australia
Prior art keywords
vaccines
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU47812/97A
Other versions
AU714930B2 (en
Inventor
Martin Friede
Nathalie Garcon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Publication of AU4781297A publication Critical patent/AU4781297A/en
Application granted granted Critical
Publication of AU714930B2 publication Critical patent/AU714930B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/11011—Alpharetrovirus, e.g. avian leucosis virus
    • C12N2740/11034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
AU47812/97A 1996-10-05 1997-09-30 Vaccines Ceased AU714930B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9620795.6A GB9620795D0 (en) 1996-10-05 1996-10-05 Vaccines
GB9620795 1996-10-05
PCT/EP1997/005578 WO1998015287A1 (en) 1996-10-05 1997-09-30 Vaccines

Publications (2)

Publication Number Publication Date
AU4781297A true AU4781297A (en) 1998-05-05
AU714930B2 AU714930B2 (en) 2000-01-13

Family

ID=10800990

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47812/97A Ceased AU714930B2 (en) 1996-10-05 1997-09-30 Vaccines

Country Status (19)

Country Link
EP (1) EP0939650A1 (en)
JP (1) JP2001501640A (en)
KR (1) KR20000048866A (en)
CN (1) CN1238696A (en)
AR (1) AR009958A1 (en)
AU (1) AU714930B2 (en)
BR (1) BR9711853A (en)
CA (1) CA2267191A1 (en)
CO (1) CO4910170A1 (en)
CZ (1) CZ116799A3 (en)
GB (1) GB9620795D0 (en)
HU (1) HUP9904549A3 (en)
IL (1) IL128985A0 (en)
NO (1) NO991524D0 (en)
NZ (1) NZ334734A (en)
PL (1) PL332633A1 (en)
TR (1) TR199900729T2 (en)
WO (1) WO1998015287A1 (en)
ZA (1) ZA978868B (en)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69840962D1 (en) * 1997-08-29 2009-08-20 Antigenics Inc ADJUVANT QS-21 CONTAINING COMPOSITIONS WITH POLYSORBATE OR CYCLODEXTRIN AS AID
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB9817052D0 (en) * 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
EP1126876B1 (en) 1998-10-16 2007-03-21 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
AU769539B2 (en) 1999-01-29 2004-01-29 Zoetis Services Llc Adjuvants for use in vaccines
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
DK1187629T3 (en) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
CN100358863C (en) 1999-09-24 2008-01-02 日本农药株式会社 Aromatic diamide derivatives or salts thereof, agricultural/norticultural chemicals and method of using the same
WO2001030847A1 (en) 1999-10-22 2001-05-03 Aventis Pasteur Limited Modified gp100 and uses thereof
AU772617B2 (en) * 1999-11-19 2004-05-06 Csl Limited Vaccine compositions
EP1235591A1 (en) * 1999-12-08 2002-09-04 Statens Veterinärmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminium salt
US6905712B2 (en) 1999-12-08 2005-06-14 Statens Veterinarmedicinska Anstalt Vaccine adjuvants comprising ginseng plant extract and added aluminum salt
ES2276788T3 (en) 2000-05-10 2007-07-01 Sanofi Pasteur Limited IMMUNOGEN POLIPEPTIDES CODED BY MAGE MINIGENS AND THEIR USES.
ES2392943T3 (en) 2000-10-18 2012-12-17 Glaxosmithkline Biologicals S.A. Anti-tumor vaccines
CA2438960A1 (en) * 2001-02-23 2002-09-06 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
EP2269639B1 (en) 2001-02-23 2018-11-28 GlaxoSmithKline Biologicals s.a. Influenza vaccine formulations for intradermal delivery
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0123580D0 (en) * 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
AU2003254585A1 (en) 2002-07-24 2004-02-16 Intercell Ag Antigens encoded by alternative reading frame from pathogenic viruses
EP2402026A3 (en) 2002-09-13 2012-04-18 Intercell AG Method for isolating hepatitis C virus peptides
AU2003285932A1 (en) 2002-10-23 2004-05-13 Glaxosmithkline Biologicals S.A. Methods for vaccinating against malaria
ES2351489T3 (en) * 2003-03-24 2011-02-07 Intercell Ag IMPROVED VACCINES.
JP4676426B2 (en) 2003-03-24 2011-04-27 インターツェル・アクチェンゲゼルシャフト Improved vaccine
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
GB0503337D0 (en) 2005-02-17 2005-03-23 Glaxosmithkline Biolog Sa Compositions
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
GB0519871D0 (en) 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US11707520B2 (en) 2005-11-03 2023-07-25 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
PL2368572T3 (en) 2005-11-04 2020-11-16 Seqirus UK Limited Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
TWI457133B (en) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa Novel composition
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
PT1962899E (en) 2005-12-22 2011-10-19 Glaxosmithkline Biolog Sa Pneumococcal polysaccharide conjugate vaccine
EA020459B1 (en) 2006-03-30 2014-11-28 Глаксосмитклайн Байолоджикалс С.А. Immunogenic composition
EA200900033A1 (en) 2006-07-18 2009-12-30 Глаксосмитклайн Байолоджикалс С.А. VACCINES AGAINST MALARIA
US8323664B2 (en) 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
JP5301455B2 (en) * 2006-11-20 2013-09-25 デューコム Use of lipid-containing particles containing Quillaja saponin to treat cancer
MX362698B (en) 2007-03-02 2019-02-01 Glaxosmithkline Biologicals Sa NOVEL METHOD and COMPOSITIONS.
BRPI0813644B8 (en) 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa immunogenic composition, vaccine, process to manufacture the same, and use of the immunogenic composition or vaccine
JP5508266B2 (en) 2007-08-13 2014-05-28 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム vaccine
AU2008352942B2 (en) 2007-12-19 2013-09-12 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Soluble forms of Hendra and Nipah virus F glycoprotein and uses thereof
GB0815872D0 (en) 2008-09-01 2008-10-08 Pasteur Institut Novel method and compositions
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
CN102307590A (en) 2009-02-10 2012-01-04 诺华有限公司 Influenza vaccines with reduced amounts of squalene
AU2010220824A1 (en) 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
SG184188A1 (en) 2010-03-26 2012-10-30 Glaxosmithkline Biolog Sa Hiv vaccine
WO2012038801A1 (en) 2010-09-21 2012-03-29 National Institute Of Immunology A spray dried powder formulation for vaccines entrapping alum and the antigen in biodegradable polymer particles
WO2012041669A1 (en) 2010-09-27 2012-04-05 Crucell Holland B.V. Heterologous prime boost vaccination regimen against malaria
CA2848611A1 (en) 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
EP2780034A1 (en) 2011-11-14 2014-09-24 Crucell Holland B.V. Heterologous prime-boost immunization using measles virus-based vaccines
WO2015092710A1 (en) 2013-12-19 2015-06-25 Glaxosmithkline Biologicals, S.A. Contralateral co-administration of vaccines
EP3504230A1 (en) 2016-08-23 2019-07-03 GlaxoSmithKline Biologicals SA Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
GB201614799D0 (en) 2016-09-01 2016-10-19 Glaxosmithkline Biologicals Sa Compositions
WO2018060288A1 (en) 2016-09-29 2018-04-05 Glaxosmithkline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
US10695424B2 (en) 2016-12-07 2020-06-30 Glaxosmithkline Biologicals S.A. Method of making a liposome composition
GB201620968D0 (en) 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides
BR112019025193A2 (en) * 2017-05-30 2020-06-23 Glaxosmithkline Biologicals S.A. METHODS OF MANUFACTURING A LIPOSOMAL ADJUVANT, MANUFACTURING A LIPOSOMAL CONCENTRATE, FOR THE PREPARATION OF AN IMMUNOGENIC COMPOSITION WITH ADJUVANT AND FOR THE PREPARATION OF A SOLUTION, LIPOSOMAL ADJUVANT, IMMUNOGENOUS COMPOUND, WITH SOLUTION,
GB201721068D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B immunisation regimen and compositions
GB201721069D0 (en) 2017-12-15 2018-01-31 Glaxosmithkline Biologicals Sa Hepatitis B Immunisation regimen and compositions
US11702674B2 (en) 2018-06-12 2023-07-18 Glaxosmithkline Biologicals Sa Simian adenovirus vectors comprising the ChAd-157 fiber protein
US20210283238A1 (en) 2018-08-07 2021-09-16 Glaxosmithkline Biologicals Sa Novel processes and vaccines
WO2020128012A1 (en) 2018-12-21 2020-06-25 Glaxosmithkline Biologicals Sa Methods of inducing an immune response
EP3934687A1 (en) 2019-03-05 2022-01-12 GlaxoSmithKline Biologicals S.A. Hepatitis b immunisation regimen and compositions
US20230109193A1 (en) * 2021-10-02 2023-04-06 Massachusetts Institute Of Technology Synergistic Combination of Alum and Non-Liposome, Non-Micelle Particle Vaccine Adjuvants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL9002314A (en) * 1990-10-23 1992-05-18 Nederlanden Staat IMMUNOGENE COMPLEXES, IN PARTICULAR ISCOMS.
US5585103A (en) * 1991-07-25 1996-12-17 Idec Pharmaceutical Corporation Induction of cytotoxic T-lymphocyte responses
ATE240117T1 (en) * 1993-03-29 2003-05-15 Pfizer MULTI-COMPONENT CLOSTRIDIAL VACCINE USING SAPONIN AS AN ADJUVANT
UA56132C2 (en) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Vaccine composition (variants), method for stabilizing qs21 providing resistance against hydrolysis (variants), method for manufacturing vaccine

Also Published As

Publication number Publication date
AU714930B2 (en) 2000-01-13
HUP9904549A3 (en) 2001-06-28
NO991524L (en) 1999-03-29
CZ116799A3 (en) 1999-08-11
TR199900729T2 (en) 1999-07-21
CN1238696A (en) 1999-12-15
WO1998015287A1 (en) 1998-04-16
AR009958A1 (en) 2000-05-17
BR9711853A (en) 1999-08-24
EP0939650A1 (en) 1999-09-08
NO991524D0 (en) 1999-03-29
IL128985A0 (en) 2000-02-17
ZA978868B (en) 1999-04-06
JP2001501640A (en) 2001-02-06
CA2267191A1 (en) 1998-04-16
NZ334734A (en) 2000-05-26
GB9620795D0 (en) 1996-11-20
HU9904549A (en) 2000-05-28
PL332633A1 (en) 1999-09-27
KR20000048866A (en) 2000-07-25
CO4910170A1 (en) 2000-04-24

Similar Documents

Publication Publication Date Title
AU4781297A (en) Vaccines
AU9623898A (en) Vaccines
AU4040197A (en) Microturbomachinery
AU3387997A (en) Autonotification
AU2845197A (en) Cycloalkano-pyridines
AU4945197A (en) Aminothiophenecarboxamides
AU4013397A (en) Arylalkanoylpyridazines
EP0958373A4 (en) Vaccines
AU4176997A (en) 3-alkyl-3-phenyl-piperidines
AU2684197A (en) Handleset
AU4218597A (en) Superseat
AU2090897A (en) Hydroxyhexahydropyridazines
AU3130597A (en) Tristetraprolin
AU5763998A (en) Chlamydia vaccines
AU4332497A (en) Endo-beta-galactosidase
AU2237197A (en) Fishing-lure
AU1900097A (en) Cremators
AU6075498A (en) Vaccines
AU3557397A (en) Double-tau-profile
AU5002897A (en) Gripper-accumulator
AU1597197A (en) Thienoquinolines
AU1643797A (en) Repeater-system
AU5016496A (en) Y-spring
AU4110897A (en) Horse-nail
ZA973824B (en) Vaccines

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired